MLYNF yields 5.96% · JNJ yields 2.13%● Live data
📍 MLYNF pulled ahead of the other in Year 1
Combined, MLYNF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MLYNF + JNJ for your $10,000?
Malayan Banking Berhad provides commercial banking and related financial products and services for individuals, small and medium enterprises, retail and corporate customers, and financial institutions primarily in Malaysia, Singapore, and Indonesia. The company operates through three segments: Group Community Financial Services, Group Global Banking, and Group Insurance and Takaful. It offers savings and fixed deposits, and current and money market accounts; and housing and personal loans, project financing, overdrafts, and trade financing, as well as remittance service. The company also offers credit cards; bancassurance products; hire purchase, unit trust, cash management, custodian, and trustee services; and treasury activities and services, including foreign exchange, money market, derivatives, and trading of capital market. In addition, it provides investment banking and securities broking services; corporate advisory, bond and equity issuance, syndicated acquisition advisory, debt restructuring advisory, and share and futures dealings; and asset and fund management services, including a range of conventional and Islamic investment solutions. Further, the company underwrites general and life insurance businesses, offshore investment life insurance business, and general and family takaful products; and offers offshore banking, property leasing and trading, nominee, property investment, IT shared and development, financial and investment advisory, money lending, private equity investments, research, and leasing and factoring services. The company operates a network of approximately 2,200 branches in 20 countries internationally. Malayan Banking Berhad was incorporated in 1960 and is headquartered in Kuala Lumpur, Malaysia.
Full MLYNF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.